Clearside Biomedical's Total Assets for the quarter that ended in Dec. 2023 was $34.02 Mil.
During the past 12 months, Clearside Biomedical's average Total Assets Growth Rate was 67.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 35.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 9.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 27.80% per year.
During the past 11 years, Clearside Biomedical's highest 3-Year average Total Assets Growth Rate was 73.10%. The lowest was -10.70%. And the median was 44.10%.
The historical data trend for Clearside Biomedical's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Clearside Biomedical's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (NAS:CLSD) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Clearside Biomedical's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Clearside Biomedical Total Assets Related Terms
Thank you for viewing the detailed overview of Clearside Biomedical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Clearside Biomedical (Clearside Biomedical) Business Description
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLSD has been successfully added to your 